Filter by: All

Matthew Patterson

Executive Chair

Peter Smith, PhD

Co-Founder, President and Chief Executive Officer

Scott Biller, PhD

Independent

Michael Rome, PhD

Foresite Capital

Kevin Bitterman, PhD

Atlas Venture

Jeff Goater

The Column Group

Christopher Burge, PhD

Massachusetts Institute of Technology

Zaven Kaprielian, PhD

Remix Therapeutics

Aaron Hoskins, PhD

University of Wisconsin

Steve Kelsey, MD

Revolution Medicines

Daniela Zarnescu, PhD

Penn State University

Aaron Gitler, PhD

Stanford University

Phillip Wong, PhD

Johns Hopkins University

Will Fairbrother, PhD

Brown University

Juan Valcarcel, PhD

Center for Genomic Regulation, Barcelona

Rui Zhao, PhD

University of Colorado

James Summers, PhD

Fmr. AbbVie

Linda Bain

Mariana Oncology

Serena Hung, MD, PhD

Independent

Benoit Chabot, PhD

University of Sherbrooke Canada

Ryan Corcoran, MD, PhD

MGH Cancer Center and Harvard Medical School
Jeff Goater
The Column Group
Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.
Kevin Bitterman, PhD
Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Michael Rome, PhD
Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Scott Biller, PhD
Independent
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Peter Smith, PhD
Co-Founder, President and Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Matthew Patterson
Executive Chair
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.
Filter by: All

Matthew Patterson

Executive Chair

Peter Smith, PhD

Co-Founder, President and Chief Executive Officer

Scott Biller, PhD

Independent

Michael Rome, PhD

Foresite Capital

Kevin Bitterman, PhD

Atlas Venture

Jeff Goater

The Column Group

Zaven Kaprielian, PhD

Remix Therapeutics

Christopher Burge, PhD

Massachusetts Institute of Technology

Aaron Hoskins, PhD

University of Wisconsin

Steve Kelsey, MD

Revolution Medicines

Daniela Zarnescu, PhD

Penn State University

Aaron Gitler, PhD

Stanford University

Phillip Wong, PhD

Johns Hopkins University

Will Fairbrother, PhD

Brown University

Juan Valcarcel, PhD

Center for Genomic Regulation, Barcelona

Rui Zhao, PhD

University of Colorado

James Summers, PhD

Fmr. AbbVie

Linda Bain

Mariana Oncology

Serena Hung, MD, PhD

Independent

Benoit Chabot, PhD

University of Sherbrooke Canada

Ryan Corcoran, MD, PhD

MGH Cancer Center and Harvard Medical School
Jeff Goater
The Column Group
Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.
Kevin Bitterman, PhD
Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Michael Rome, PhD
Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Scott Biller, PhD
Independent
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Peter Smith, PhD
Co-Founder, President and Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Matthew Patterson
Executive Chair
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.
Filter by: All

Matthew Patterson

Executive Chair

Peter Smith, PhD

Co-Founder, President and Chief Executive Officer

Scott Biller, PhD

Independent

Michael Rome, PhD

Foresite Capital

Kevin Bitterman, PhD

Atlas Venture

Jeff Goater

The Column Group

Christopher Burge, PhD

Massachusetts Institute of Technology

Zaven Kaprielian, PhD

Remix Therapeutics

Aaron Hoskins, PhD

University of Wisconsin

Steve Kelsey, MD

Revolution Medicines

Daniela Zarnescu, PhD

Penn State University

Aaron Gitler, PhD

Stanford University

Phillip Wong, PhD

Johns Hopkins University

Will Fairbrother, PhD

Brown University

Juan Valcarcel, PhD

Center for Genomic Regulation, Barcelona

Rui Zhao, PhD

University of Colorado

James Summers, PhD

Fmr. AbbVie

Linda Bain

Mariana Oncology

Serena Hung, MD, PhD

Independent

Benoit Chabot, PhD

University of Sherbrooke Canada

Ryan Corcoran, MD, PhD

MGH Cancer Center and Harvard Medical School
Jeff Goater
The Column Group
Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.
Kevin Bitterman, PhD
Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Michael Rome, PhD
Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Scott Biller, PhD
Independent
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Peter Smith, PhD
Co-Founder, President and Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Matthew Patterson
Executive Chair
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.
Filter by: All

Matthew Patterson

Executive Chair

Peter Smith, PhD

Co-Founder, President and Chief Executive Officer

Scott Biller, PhD

Independent

Michael Rome, PhD

Foresite Capital

Kevin Bitterman, PhD

Atlas Venture

Jeff Goater

The Column Group

Zaven Kaprielian, PhD

Remix Therapeutics

Christopher Burge, PhD

Massachusetts Institute of Technology

Aaron Hoskins, PhD

University of Wisconsin

Steve Kelsey, MD

Revolution Medicines

Daniela Zarnescu, PhD

Penn State University

Aaron Gitler, PhD

Stanford University

Phillip Wong, PhD

Johns Hopkins University

Will Fairbrother, PhD

Brown University

Juan Valcarcel, PhD

Center for Genomic Regulation, Barcelona

Rui Zhao, PhD

University of Colorado

James Summers, PhD

Fmr. AbbVie

Linda Bain

Mariana Oncology

Serena Hung, MD, PhD

Independent

Benoit Chabot, PhD

University of Sherbrooke Canada

Ryan Corcoran, MD, PhD

MGH Cancer Center and Harvard Medical School
Jeff Goater
The Column Group
Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.
Kevin Bitterman, PhD
Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Michael Rome, PhD
Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Scott Biller, PhD
Independent
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Peter Smith, PhD
Co-Founder, President and Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Matthew Patterson
Executive Chair
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.
Filter by: All

Matthew Patterson

Executive Chair

Peter Smith, PhD

Co-Founder, President and Chief Executive Officer

Scott Biller, PhD

Independent

Michael Rome, PhD

Foresite Capital

Kevin Bitterman, PhD

Atlas Venture

Jeff Goater

The Column Group

Zaven Kaprielian, PhD

Remix Therapeutics

Christopher Burge, PhD

Massachusetts Institute of Technology

Aaron Hoskins, PhD

University of Wisconsin

Steve Kelsey, MD

Revolution Medicines

Daniela Zarnescu, PhD

Penn State University

Aaron Gitler, PhD

Stanford University

Phillip Wong, PhD

Johns Hopkins University

Will Fairbrother, PhD

Brown University

Juan Valcarcel, PhD

Center for Genomic Regulation, Barcelona

Rui Zhao, PhD

University of Colorado

James Summers, PhD

Fmr. AbbVie

Linda Bain

Mariana Oncology

Serena Hung, MD, PhD

Independent

Benoit Chabot, PhD

University of Sherbrooke Canada

Ryan Corcoran, MD, PhD

MGH Cancer Center and Harvard Medical School
Jeff Goater
The Column Group
Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.
Kevin Bitterman, PhD
Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Michael Rome, PhD
Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Scott Biller, PhD
Independent
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Peter Smith, PhD
Co-Founder, President and Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Matthew Patterson
Executive Chair
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.
Filter by: All

Matthew Patterson

Executive Chair

Peter Smith, PhD

Co-Founder, President and Chief Executive Officer

Scott Biller, PhD

Independent

Michael Rome, PhD

Foresite Capital

Kevin Bitterman, PhD

Atlas Venture

Jeff Goater

The Column Group

Zaven Kaprielian, PhD

Remix Therapeutics

Christopher Burge, PhD

Massachusetts Institute of Technology

Aaron Hoskins, PhD

University of Wisconsin

Steve Kelsey, MD

Revolution Medicines

Daniela Zarnescu, PhD

Penn State University

Aaron Gitler, PhD

Stanford University

Phillip Wong, PhD

Johns Hopkins University

Will Fairbrother, PhD

Brown University

Juan Valcarcel, PhD

Center for Genomic Regulation, Barcelona

Rui Zhao, PhD

University of Colorado

James Summers, PhD

Fmr. AbbVie

Linda Bain

Mariana Oncology

Serena Hung, MD, PhD

Independent

Benoit Chabot, PhD

University of Sherbrooke Canada

Ryan Corcoran, MD, PhD

MGH Cancer Center and Harvard Medical School
Jeff Goater
The Column Group
Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.
Kevin Bitterman, PhD
Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Michael Rome, PhD
Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Scott Biller, PhD
Independent
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Peter Smith, PhD
Co-Founder, President and Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Matthew Patterson
Executive Chair
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.
Filter by: All

Matthew Patterson

Executive Chair

Peter Smith, PhD

Co-Founder, President and Chief Executive Officer

Scott Biller, PhD

Independent

Michael Rome, PhD

Foresite Capital

Kevin Bitterman, PhD

Atlas Venture

Jeff Goater

The Column Group

Christopher Burge, PhD

Massachusetts Institute of Technology

Zaven Kaprielian, PhD

Remix Therapeutics

Aaron Hoskins, PhD

University of Wisconsin

Steve Kelsey, MD

Revolution Medicines

Daniela Zarnescu, PhD

Penn State University

Aaron Gitler, PhD

Stanford University

Phillip Wong, PhD

Johns Hopkins University

Will Fairbrother, PhD

Brown University

Juan Valcarcel, PhD

Center for Genomic Regulation, Barcelona

Rui Zhao, PhD

University of Colorado

James Summers, PhD

Fmr. AbbVie

Linda Bain

Mariana Oncology

Serena Hung, MD, PhD

Independent

Benoit Chabot, PhD

University of Sherbrooke Canada

Ryan Corcoran, MD, PhD

MGH Cancer Center and Harvard Medical School
Jeff Goater
The Column Group
Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.
Kevin Bitterman, PhD
Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Michael Rome, PhD
Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Scott Biller, PhD
Independent
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Peter Smith, PhD
Co-Founder, President and Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Matthew Patterson
Executive Chair
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.
Filter by: All

Matthew Patterson

Executive Chair

Peter Smith, PhD

Co-Founder, President and Chief Executive Officer

Scott Biller, PhD

Independent

Michael Rome, PhD

Foresite Capital

Kevin Bitterman, PhD

Atlas Venture

Jeff Goater

The Column Group

Christopher Burge, PhD

Massachusetts Institute of Technology

Zaven Kaprielian, PhD

Remix Therapeutics

Aaron Hoskins, PhD

University of Wisconsin

Steve Kelsey, MD

Revolution Medicines

Daniela Zarnescu, PhD

Penn State University

Aaron Gitler, PhD

Stanford University

Phillip Wong, PhD

Johns Hopkins University

Will Fairbrother, PhD

Brown University

Juan Valcarcel, PhD

Center for Genomic Regulation, Barcelona

Rui Zhao, PhD

University of Colorado

James Summers, PhD

Fmr. AbbVie

Linda Bain

Mariana Oncology

Serena Hung, MD, PhD

Independent

Benoit Chabot, PhD

University of Sherbrooke Canada

Ryan Corcoran, MD, PhD

MGH Cancer Center and Harvard Medical School
Jeff Goater
The Column Group
Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.
Kevin Bitterman, PhD
Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Michael Rome, PhD
Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Scott Biller, PhD
Independent
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Peter Smith, PhD
Co-Founder, President and Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Matthew Patterson
Executive Chair
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.
Filter by: All

Matthew Patterson

Executive Chair

Peter Smith, PhD

Co-Founder, President and Chief Executive Officer

Scott Biller, PhD

Independent

Michael Rome, PhD

Foresite Capital

Kevin Bitterman, PhD

Atlas Venture

Jeff Goater

The Column Group

Christopher Burge, PhD

Massachusetts Institute of Technology

Zaven Kaprielian, PhD

Remix Therapeutics

Aaron Hoskins, PhD

University of Wisconsin

Steve Kelsey, MD

Revolution Medicines

Daniela Zarnescu, PhD

Penn State University

Aaron Gitler, PhD

Stanford University

Phillip Wong, PhD

Johns Hopkins University

Will Fairbrother, PhD

Brown University

Juan Valcarcel, PhD

Center for Genomic Regulation, Barcelona

Rui Zhao, PhD

University of Colorado

James Summers, PhD

Fmr. AbbVie

Linda Bain

Mariana Oncology

Serena Hung, MD, PhD

Independent

Benoit Chabot, PhD

University of Sherbrooke Canada

Ryan Corcoran, MD, PhD

MGH Cancer Center and Harvard Medical School
Jeff Goater
The Column Group
Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.
Kevin Bitterman, PhD
Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Michael Rome, PhD
Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Scott Biller, PhD
Independent
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Peter Smith, PhD
Co-Founder, President and Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Matthew Patterson
Executive Chair
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.
Filter by: All

Matthew Patterson

Executive Chair

Peter Smith, PhD

Co-Founder, President and Chief Executive Officer

Scott Biller, PhD

Independent

Michael Rome, PhD

Foresite Capital

Kevin Bitterman, PhD

Atlas Venture

Jeff Goater

The Column Group

Christopher Burge, PhD

Massachusetts Institute of Technology

Zaven Kaprielian, PhD

Remix Therapeutics

Aaron Hoskins, PhD

University of Wisconsin

Steve Kelsey, MD

Revolution Medicines

Daniela Zarnescu, PhD

Penn State University

Aaron Gitler, PhD

Stanford University

Phillip Wong, PhD

Johns Hopkins University

Will Fairbrother, PhD

Brown University

Juan Valcarcel, PhD

Center for Genomic Regulation, Barcelona

Rui Zhao, PhD

University of Colorado

James Summers, PhD

Fmr. AbbVie

Linda Bain

Mariana Oncology

Serena Hung, MD, PhD

Independent

Benoit Chabot, PhD

University of Sherbrooke Canada

Ryan Corcoran, MD, PhD

MGH Cancer Center and Harvard Medical School
Jeff Goater
The Column Group
Jeff Goater is a Venture Partner at The Column Group (TCG). Previously, Jeff served as interim Chief Executive Officer of the TCG portfolio company Atavistik Bio and before that Chief Executive Officer of Surface Oncology. During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to Surface, he served as Chief Financial Officer of Voyager Therapeutics where he was one of the members of the founding management team. While at Voyager, he led its crossover financing, initial public offering and strategic partnership with Sanofi Genzyme. Previously he spent nearly a decade in investment banking, most recently as a managing director at Evercore Partners, advising on more than $100 billion in strategic transactions in the biopharma industry. He began his career as a research scientist in the field of AAV gene therapy. Jeff holds master’s degrees in microbiology/immunology (M.S.), pathology (M.S.) and business administration (M.B.A.) from the University of Rochester.
Kevin Bitterman, PhD
Atlas Venture
Kevin focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Navitor Pharmaceuticals. He is a co-founder and board member of Disc Medicine and is chair of the board of Vedere Bio II following Novartis’ acquisition of Vedere Bio, Inc. He was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic and Visterra (acquired by Otsuka), and co-founded Genocea Biosciences (NASDAQ: GNCA). Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004. Kevin completed his PhD in genetics at Harvard Medical School.
Michael Rome, PhD
Foresite Capital
Michael joined Foresite Capital in 2016 and is active in the firm’s private and public market investments. Michael is a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his PhD in biochemistry from Caltech as an NSF graduate research fellow and has more than 12 years of experience as a research scientist, having authored numerous publications in biomedical research journals.
Scott Biller, PhD
Independent
Scott is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates. Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb. During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. Scott earned a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.
Peter Smith, PhD
Co-Founder, President and Chief Executive Officer
Pete is Co-Founder and Chief Executive Officer of Remix Therapeutics. Peter currently leads fundraising, strategy, hiring and other tasks at Remix while also directing all scientific activities. He brings extensive drug discovery experience to the team, most recently serving as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. Peter received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.
Matthew Patterson
Executive Chair
Matt Patterson is biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition by Astellas Pharma Inc. in January 2020. Matt was also Chairman of the Board of Directors and formerly served as President until May 2018. Previously he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed.

Matt is a member of the Board of Directors of Homology Medicines, Inc., Vor Biopharma, Inc., Remix Therapeutics, Inc., and 5:01 Acquisition Corporation. He is also a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector. He served as Chairman of ARM in 2019 and 2020.  Matt received his Bachelor’s degree in Biochemistry from Bowdoin College.